Literature DB >> 17406606

Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.

Subhash C Sinha1, Sanjib Das, Lian-Sheng Li, Richard A Lerner, Carlos F Barbas.   

Abstract

This protocol describes the preparation of Ab constructs using agents that target cells expressing integrins alpha(v)beta3 and alpha(v)beta5, and the monoclonal aldolase Ab 38C2. The targeting agents are equipped with a diketone or vinylketone linker, and selectively react through the reactive Lys residues in the Ab binding sites to form 38C2 conjugates or chemically programmed 38C2 (i.e., cp38C2). The targeting agent possessing a diketone linker reacts with the Lys residues forming an enaminone derivative. By contrast, the vinylketone linker is used as the corresponding acetone adduct (i.e., a pro-vinylketone linker), and this pro-adapter undergoes a 38C2-catalyzed retro-aldol reaction to produce the vinylketone linker, which forms a Michael-type adduct with the Lys residues. The Ab construct formation is achieved in <1 h for the diketone compounds at ambient temperature, and in 2-16 h using the pro-vinylketone linker at 37 degrees C. The 38C2 constructs are retargeted to cells over-expressing integrins, and are potential candidates for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406606     DOI: 10.1038/nprot.2007.3

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  17 in total

1.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

2.  Multiple catalytic aldolase antibodies suitable for chemical programming.

Authors:  Rajib Kumar Goswami; Zheng-Zheng Huang; Jane S Forsyth; Brunhilde Felding-Habermann; Subhash C Sinha
Journal:  Bioorg Med Chem Lett       Date:  2009-04-18       Impact factor: 2.823

3.  Instant immunity through chemically programmable vaccination and covalent self-assembly.

Authors:  Mikhail Popkov; Beatriz Gonzalez; Subhash C Sinha; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

4.  Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Authors:  Shigehiro Asano; Julia Gavrilyuk; Dennis R Burton; Carlos F Barbas
Journal:  ACS Med Chem Lett       Date:  2014-02-13       Impact factor: 4.345

Review 5.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

6.  Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.

Authors:  Yuan Liu; Rajib K Goswami; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2015-06-09       Impact factor: 4.939

7.  Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.

Authors:  Julia I Gavrilyuk; Ulrich Wuellner; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2009-01-15       Impact factor: 2.823

8.  Chemically Programmed Bispecific Antibodies in Diabody Format.

Authors:  Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

9.  An efficient chemical approach to bispecific antibodies and antibodies of high valency.

Authors:  Julia I Gavrilyuk; Ulrich Wuellner; Syed Salahuddin; Rajib K Goswami; Subhash C Sinha; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

10.  A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.

Authors:  Masahiko Hayakawa; Narihiro Toda; Nancy Carrillo; Natalie J Thornburg; James E Crowe; Carlos F Barbas
Journal:  Chembiochem       Date:  2012-09-10       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.